Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

In silico and intuitive predictions of cyp46a1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Mast, N.
  • Linger, M.
  • Clark, M.
  • Wiseman, J.
  • Stout, C. David
  • Pikuleva, I. A.

publication date

  • November 2012

journal

  • Molecular Pharmacology  Journal

abstract

  • Cytochrome P450 46A1 (cholesterol 24-hydroxylase) is an important brain enzyme that may be inhibited by structurally distinct pharmaceutical agents both in vitro and in vivo. To identify additional inhibitors of CYP46A1 among U.S. Food and Drug Administration-approved therapeutic agents, we used in silico and intuitive predictions and evaluated some of the predicted binders in the enzyme and spectral binding assays. We tested a total of 298 marketed drugs for the inhibition of CYP46A1-mediated cholesterol hydroxylation in vitro and found that 13 of them reduce CYP46A1 activity by >50%. Of these 13 inhibitors, 7 elicited a spectral response in CYP46A1 with apparent spectral K(d) values in a low micromolar range. One of the identified tight binders, the widely used antidepressant fluvoxamine, was cocrystallized with CYP46A1. The structure of this complex was determined at a 2.5 Å resolution and revealed the details of drug binding to the CYP46A1 active site. The NH(2)-containing arm of the Y-shaped fluvoxamine coordinates the CYP46A1 heme iron, whereas the methoxy-containing arm points away from the heme group and has multiple hydrophobic interactions with aliphatic amino acid residues. The CF(3)-phenyl ring faces the entrance to the substrate access channel and has contacts with the aromatic side chains. The crystal structure suggests that only certain drug conformers can enter the P450 substrate access channel and reach the active site. Once inside the active site, the conformer probably further adjusts its configuration and elicits the movement of the protein side chains.

subject areas

  • Animals
  • Antidepressive Agents
  • Brain
  • Cattle
  • Cholesterol
  • Computer Simulation
  • Crystallization
  • Crystallography, X-Ray
  • Entropy
  • Enzyme Assays
  • Fluvoxamine
  • Humans
  • Hydroxylation
  • In Vitro Techniques
  • Microsomes
  • Models, Molecular
  • Molecular Structure
  • Protease Inhibitors
  • Protein Binding
  • Quantitative Structure-Activity Relationship
  • Recombinant Proteins
  • Stereoisomerism
  • Steroid Hydroxylases
  • Tranylcypromine
  • Water
scroll to property group menus

Identity

PubMed Central ID

  • PMC3477228

International Standard Serial Number (ISSN)

  • 0026-895X

Digital Object Identifier (DOI)

  • 10.1124/mol.112.080424

PubMed ID

  • 22859721
scroll to property group menus

Additional Document Info

start page

  • 824

end page

  • 834

volume

  • 82

issue

  • 5

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support